Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma

This study has been terminated.
(Study closed following Phase I portion, insufficient activity to continue to Phase II.)
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT00354523
First received: July 18, 2006
Last updated: December 16, 2014
Last verified: December 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: August 2013
  Primary Completion Date: November 2006 (Final data collection date for primary outcome measure)
No publications provided by M.D. Anderson Cancer Center

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):